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doses. Further research is required to conﬁrm whether
such gender disparities persist, and, if so, whether they
are justiﬁed. Additional research linking quality with 
outcomes of care are necessary to determine their effects
on the outcomes of children with ADHD. In this way,
researchers and clinicians can work together to translate
ﬁndings into better patient care.
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OBJECTIVE: To determine the association between
asthma and generalized anxiety disorder for adults utiliz-
ing a PBM. METHODS: Adult participants (age 18–65
years) were retrospectively identiﬁed in Caremark’s PBM
database and assessed for asthma and generalized anxiety
disorder (GAD) from January 2002–September 2002.
Using pharmacy algorithms, asthmatic participants and
non-asthmatic participants were identiﬁed and compared
as having GAD where anxiety medication supply
exceeded 27 days. Sub-analysis of the asthma popula-
tion compared the utilization of speciﬁc drug classes to
the association of anxiety disorder. All populations were
compared using odds ratio analysis. RESULTS: A total 
of 4,238,840 participants (58.5% female) were evaluated
over the study period; 205,964 (4.86%) were identiﬁed
as being asthmatic (60.2% female, mean age 51.5 years,
std 15.7 years); 210,972 (4.98%) of the study population
were being treated with anti-anxiety medications; and
16,912 (0.4%) of the participants were treated with both.
Asthma was associated with a signiﬁcant increased 
likelihood of anxiety disorder (OR: 1.77; 95% CI: 1.74
to 1.80). Treatment with steroid inhalants and/or
leukotriene modulators was associated with a signiﬁcant
decrease in the likelihood of anxiety disorders among
asthmatics (OR: 0.89; 95% CI: 0.87 to 0.92). While treat-
ment with asthma combination medications was associ-
ated with a higher signiﬁcant increased likelihood of GAD
among asthmatics (OR: 2.22; 95% CI: 1.72 to 2.86).
CONCLUSION: These ﬁndings are consistent with pre-
viously published self-reported data showing an associa-
tion between asthma and GAD. In this study, participants
treated for asthma were found to be 77% more likely to
be treated for GAD than the general non-asthmatic 
population. Participants using steroid inhalants or
leukotriene modulators were 11% less likely to be treated
for GAD than other asthmatics. The use of asthma 
combination therapy was associated with 120%
increased likelihood of GAD treatment, possibly indicat-
ing the severity of the asthma condition is correlated to
an increased likelihood of GAD. Increased attention
needs to be placed on the management of anxiety as a
comorbidity of asthma.
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OBJECTIVES: HEDIS guidelines recommend patients
with depression remain on antidepressant therapy for a
minimum of six months to receive full clinical beneﬁt.
This study compared differences in healthcare costs based
upon length of SSRI therapy. METHODS: Continuously
eligible patients >18 years of age receiving SSRI therapy
diagnosed as having depression in a managed Medicaid
program from July 1, 1999 to December 31, 2000 were
eligible for study inclusion. Length of therapy was deﬁned
as total SSRI days supply acquired within six months of
the index date. Patients were placed into the following
cohorts based upon length of therapy or drug utilization
patterns: 1) <90 days; 2) 90–179 days; 3) >180 days; or
4) Switched/Augmented (SA). Differences in pharmaceu-
tical, professional, hospital and total healthcare costs
were evaluated across the four cohorts over a 1-year
follow-up period. RESULTS: There were 2250 patients
meeting all inclusion criteria. Only 34% of patients
received >180 days of therapy. While 24% had <90 days
of therapy, 21% had 90–179 days and 21% had evidence
of switching/augmentation. Demographic and back-
ground covariates were similar across all cohorts. As
expected, pharmaceutical charges increased as length 
of therapy increased, being highest in the SA cohort.
However, as length of therapy increased from <90 days
to >180 days, professional services and hospital charges
decreased by an average of $816 annually per patient.
Total monthly healthcare costs in the >180 day cohort
remained stable after at least 6 months of SSRI treatment
through the full 12-months that patients were followed.
CONCLUSIONS: Pharmaceutical costs increased as SSRI
length of therapy improves. However, healthcare costs
decreased due to reductions in hospital and professional
service charges for patients maintained on SSRIs for at
least the recommended six months of continuous therapy.
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OBJECTIVE: There is little research describing the effects
of the introduction of generic ﬂuoxetine to the SSRI
market. The purpose of this analysis is to examine uti-
lization of the SSRI class in a Pennsylvania Medicaid
HMO before and after the launch of ﬂuoxetine (generic)
